Devices, compositions and methods for colonic microbiome engraftment
OwnerThomas Julius BORODY, Antony MILIS +1inventors
InventorsThomas Julius BORODY, Antony MILIS, Annabel Kate CLANCY
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.
Claims21
An aqueous liquid formulation comprising:
- (a) a soap,
- (b) at least one compound or composition comprising, or selected from the group consisting of:
- (i) at least one biofilm disrupting agent comprising at least one enzyme;
- (ii) at least one antibiotic;
- (iii) at least composition selected from the group consisting of:
- a N-acetylcysteine, dispersin, ribonucleic-acid-III inhibiting peptide (RIP), Salvadora persica extracts, competence-stimulating peptide (CSP) patulin (PAT), penicillic acid (PA)/EDTA, cathelicidin-derived peptides, small lytic peptide PTP-7, nitric oxide, cys-2-decenoic acid, sodium nitroprusside, s-nitroso-l-glutathione (GSNfaO), s-nitroso-N-acetylpenicillamine (SNAP), chlorhexidine, iodine, povidone-iodine (P1) (or WOKADINE™, PYODINE™, BETADINE™), a nanoemulsion, a lytic bacteriophage, a lactoferrin, a xylitol hydrogel, a synthetic iron chelator, a cranberry component, a curcumin, an acetyl-11-keto-boswellic acid (AKBA), a barley coffee (BC) component, a silver nanoparticle, a metallic silver or a silver ion, a probiotic (and optionally the probiotic comprises a Bacillus), sinefungin, N-acetyl-cysteine, S-adenosylmethionine, S-adenosyl-homocysteine, a Delisea furanone, a N-sulfonyl homoserine lactone, iron or ionic silver salts (which can inhibit film formation, and permit antibiotics to be more active), arsenicals, selenium, titanium dioxide, gallium nitrate, an alcohol such as ethanol, hydrogen peroxide, hydrochloric acid, formaldehyde or luminal formalin in low concentrations, ozonated water, hydrogenated water, activated or electrolyzed water, a super-oxidized aqueous solution (optionally OXUM™, MICRODACYN™, DERMACYN™), nitrofurantoin (e.g., MACROBID™), hexamine hippurate (e.g., HIPREX™), potassium hydroxide, mercuric chloride, boric or boronic acid, disodium EDTA, a phytocannabinoid, optionally cannabidiol (CBD), an alkyl dimethylol alkanate (ADMA), or any mixture or combination thereof;
- (iv) at least one polyol or a wetting agent;
- (v) at least one surfactant or biosurfactant;
- (vi) at least one anti-quorum sensing (QS) compound;
- (vii) at least one prebiotic,
- and optionally the at least one prebiotic comprises:
- inulin, a chicory extract, a fructan-comprising dietary fiber, N-acetyl glucosamine (NAG), an apple extract such as apple pectin, peas, tomato, rice and garlic or extracts thereof;
- (viii) a stain and/or a dye,
- wherein optionally the stain or dye comprises Coomassie Brilliant Blue, triarylmethane dye, rhodamine or erythrosine B;
- (ix) a stool softening agent or a laxative,
- wherein optionally the stool softening agent or laxative comprises:
- glycerin, sorbitol, lactulose, polyethylene glycol (PEG), a docusate, a docusate salts or a dioctyl sulfosuccinate or a mixture thereof;
- (x) a charcoal, a carbon or equivalent (e.g., CHARCODOTE™), for example, an activated carbon or charcoal, wherein optionally the carbon or charcoal or equivalent is added at a concentration of between about 1 to 100 grams per liter,
- and optionally the activated carbon or charcoal is or is formulated as a powdered, granular or extruded activated carbon or charcoal, or is formulated as a bead-activated, woven or polymer-coated carbon;
- (xi) an ascorbic acid or fatty acid ester thereof, ascorbyl palmitate, sodium ascorbate, potassium ascorbate, calcium ascorbate or vitamin C, or a liposome comprising the ascorbic acid or fatty acid ester thereof, ascorbyl palmitate, sodium ascorbate, potassium ascorbate, calcium ascorbate or vitamin C, wherein optionally the ascorbic acid or fatty acid ester thereof, ascorbyl palmitate, sodium ascorbate, potassium ascorbate, calcium ascorbate or vitamin C is present in the formulation at a concentration of between about 1 ugm/ml to about 1 gm/ml;
- (xii) pure (or substantially pure) or distilled water (H2O) (optionally alkaline water), optionally used alone as a biofilm dissolver exploiting its hypotonic nature to penetrate bacteria resulting in swelling and bursting of the bacteria or other pathogen, and optionally the pure, alkaline or distilled water is used as an enema,
- and optionally the enema or a colonic washing is by infusing infused the pure, alkaline or distilled water by use of a colonic machine or equivalent, or by use of a naso-gastric (NG) long tube, or equivalent, and optionally ozone or ozonated water is administered after administration of the pure, alkaline or distilled water;
- (xiii) iodine, povidone, povidone-iodine (PI), optionally at a between about 50% to 0.1% concentration delivered to the GI tract;
- optionally the iodine, povidone, povidone-iodine (PI) is alone or combined with another liquid or a solvent, optionally pure water, and optionally ozone or ozonated water is administered after administration of the pure, alkaline, alkalized or distilled water;
- (xiv) an anti-persister cell therapy comprising administration of a compound that can activate a persister cell (optionally a persister bacterial cell) and thereby destroy, neutralize or kill the persister cell by administration (optionally by co-administration) of an antibiotic or a biofilm disrupting or a biofilm-related therapy,
- and optionally the anti-persister cell therapy compound and/or the antibiotic or biofilm disrupting or biofilm-related therapy is delivered orally, optionally is ingested as a tablet, geltab or a capsule, optionally for between about 1 to 30 days (d) before a biofilm-disrupting or a biofilm-removal therapy,
- and optionally the anti-persister cell therapy compound and/or the antibiotic or biofilm disrupting or biofilm-related therapy is delivered or administered via use of a colonic washout machine or equivalent, or a colonoscope or equivalent, or by use of an overtube or equivalent,
- and optionally water, saline, a soap and water mixture, a super-oxidized solution (SOS) (also known as anolyte solution, or oxidative potential water), is used as a dissolving or suspending liquid,
- and optionally the anti-persister cell therapy compound comprises mitamycin-C, 5-fluorouracil (or ADRUCIL™), cisplatin (or PLATINOL™), cis-2-decenoic acid, dispersin-B (or DspB), a halogenated phenazine (NP) (optionally 2,4-dibrominated HP, or equivalents of mixtures thereof,
- and optionally the anti-persister cell therapy (to activate resister bacteria in biofilm matrix) comprises pyruvate, a sugar and/or a polyol (optionally a sugar alcohol), and optionally the sugar and/or a polyol comprises mannitol, glucose or fructose or combination thereof;
- (xv) a super-oxidized solution (SOS) (also known as anolyte solution, or oxidative potential water) (optionally as MICRODACYN™ or MICROCYN™) optionally used alone as biofilm-removing or biofilm-disrupting agent, optionally administered via a colonic washing machine or equivalent, an overtube or equivalent with colonoscope or equivalent, or via a colonoscope or a nasogastric (NJ) tube or equivalents, and optionally a volume of between about 1 to 36 liters (L) of the solution is used;
- (xvi) an ozonated water, optionally used alone as a biofilm-removing or biofilm-disrupting liquid, and optionally is administered using methods described in (xiv) for super-oxidized solutions (SOS);
- (xvii) an ozone gas (which may damage a biofilm and/or its resident organisms, and optionally is administered as an insulated gas, optionally administered via a colonoscope or equivalent or by using gas bags or equivalent,
- and optionally ozone is administered during a colonoscopy, optionally either in air or with CO2 as insufflating gases,
- and optionally the ozone gas is substituted or replaced by CO2, and optionally the ozone gas is aspirated and rapidly replaced by CO2 prior to infusing a fecal microbiota transplantation (FMT) material so as not to damage incoming microbiota;
- (xviii) N-acetyl-cysteine (NAC), optionally administered alone, optionally administered via or into a rectum (optionally administered as described via methods described in (xiv) above) optionally administered intravenously (IV), optionally administered in high gram doses of between about 250 mg to 50 grams;
- (xix) a Vitamin C or L-ascorbic acid, optionally administered as a bowel prep, optionally administered before or during a colonic machine or equivalent wash or administered before or during a colonoscopy;
- optionally administered as an ascorbic acid and sodium ascorbate mixture (optionally administered with a polyethylene glycol or a formulation of:
- polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride as an oral solution,
- optionally administered at a dose of about 11 gram (g) or more, or optionally administered in a dose of about 45 grams (g), 50 g, or 55 g or more, or at between about 40 g and 60 g, or 30 g and 75 g, or 10 g and 100 g,
- and optionally the Vitamin C or L-ascorbic acid is administered orally (optionally wash out luminal fecal material and to dissolve a biofilm simultaneously,
- and optionally the Vitamin C or L-ascorbic acid is administered with an enema, optionally at a sodium ascorbate or ascorbic acid formulated or administered in a dose of between about 1 gram (g) to 100 g,
- and optionally can be administered as described in (xiv);
- and/or
- (xx) the at least one compound or composition comprises any combination of (i) to (xix).
12-13. (canceled)
A pair of pants or shorts for use with a colonic washout machine, bed or chair, wherein the pair of pants comprises:
- an orifice or opening sufficient to allow passage of a tube, optionally an enema tube or colonoscopic tube;
- and a clip, clamp or adhesive (or a plurality of clips, clamps or adhesives) or equivalent thereof capable of securing the tube to the pants or shorts such that the tube does not slip out of or through the orifice or opening, and optionally the pair of pants or shorts is sufficiently tight-fitting such that the pants or shorts can hold the tube in place against a pressure or pulling force on the tube that, but without the tube being secured to the pants or shorts with the fitting, tie, snap, clip, clamp or adhesive or equivalent thereof, the tube would move through the orifice or opening, wherein optionally the pair of pants or shorts is made of, or comprises, an elastic material.
A colonic washout machine or device, wherein optionally the colonic washout machine or device is manufactured or configured in the form of a bed or a chair, optionally a movable bed or chair, and the colonic washout machine or device comprises a hole or opening approximate to the position of the anus of an individual sitting or laying on the colonic washout machine or device, wherein the hole or opening is sufficiently large to allow passage of a tube or device, optionally a rectal speculum or catheter, an endoscope, a colonoscope or a colonic tube,
- wherein the colonic washout machine or device optionally further comprises:
- (a) an auxiliary container or containers, or liquid or formulation holding modules, capable of holding a liquid or formulation attached to the colonic washout machine or device (optionally removably attached) and operatively attached or directly or indirectly connected to an endoscope, colonoscope or rectal speculum or catheter designed for insertion into a colon, and optionally the auxiliary container or containers are operatively attached or connected to the rectal speculum or catheter by use of a second tube,
- and optionally the auxiliary container or containers further comprise a value or valves disposed between the auxiliary container or containers and the rectal speculum or catheter, wherein the value or valves are capable of controlling the rate of flow of liquid or formulation from the auxiliary container or containers to the rectal speculum or catheter, or the value or valves are capable of turning on or off the flow of liquid or formulation from the auxiliary container or containers to the rectal speculum or catheter,
- and optionally the colonic washout machine or device further comprises or incorporates one or more intake ports, cassette spaces or cavities, each which can take (or input) a cassette, cartridge or a removable cartridge housing, and optionally the removable cartridge housing is fitted to have inserted therein a cassette or a cartridge,
- and optionally the cassette or cartridge comprises or has contained therein a liquid, formulation, powder or lyophilate formulation for dissolving a biofilm;
- a drug or an active agent;
- or, an FMT material,
- and optionally the colonic washout machine or device further comprises a pump or pumps operably connected to the rectal speculum or catheter, the auxiliary container or containers, or the second tube to move or facilitate the flow of liquid or formulation contents of the auxiliary container or containers out to a liquid or formulation flowing through the rectal speculum or catheter,
- and optionally the pump or pumps are capable or programmed to create a water hammer effect, which is created by a rapid back and forth movement of a water or liquid or formulation column for a short distance, for example, for a distance of between about 0.5 to 10 cm, or between about 1 mm to 5 cm, and the pump or pumps comprise or use a piston-driven system or equivalent such that a water or liquid column is induced to have a back-and-forth movement in situ,
- and optionally the colonic washout machine or device further comprises a warming module, heater or heating unit to heat a fluid or liquid or formulation in the auxiliary container or containers, or the tubes, to about body temperature,
- and optionally the device (optionally the one or more intake ports, or cavities, or cassette or cartridge housings) further comprise an thermometer or thermostat capable of reading the temperature of a liquid or formulation, and thermometer or thermostat are capable of controlling the temperature of the liquid or formulation, where the liquid or formulation or fluid can be warmed and/or maintained at approximate body temperature, or the liquid or formulation or fluid can be warmed and/or maintained at about 37° C.,
- and optionally the thermometer or thermostat is remotely read and/or is remotely controlled, for example, by a hand-held device or a computer,
- and optionally the auxiliary container or containers, the cassette or cartridge, the cassette or cartridge housing, or the second tube, comprise a filter or filters capable of separating or straining a particulate matter from a liquid or formulation before it is infused into the colon, and optionally the auxiliary container or containers, the cassette or cartridge, the cassette or cartridge housing, or the second tube, comprise fitting that allow removal or exchange of or insertion of a new filter or filters;
- (b) a master container or containers capable of holding liquids or formulations for infusion into a colon, wherein optionally the master container or containers are operatively connected to the auxiliary container or containers of (a), and the master container or containers are operatively attached or connected to a rectal speculum or catheter, and optionally the master container or containers are operatively attached or connected to the rectal speculum or catheter by use of a third tube,
- and optionally the master container or containers further comprise a value or valves disposed between the master container or containers and the rectal speculum or catheter, wherein the value or valves are capable of controlling the rate of flow of liquid or formulation from the master container or containers to the rectal speculum or catheter, or the value or valves are capable of turning on or off the flow of liquid or formulation from the master container or containers to the rectal speculum or catheter,
- and optionally the colonic washout machine or device further comprises a pump operably connected to the rectal speculum or catheter, the master container or containers, or the third tube to move or facilitate the flow of liquid or formulation contents of the master container or containers out to a liquid or formulation flowing through the rectal speculum or catheter,
- and optionally the colonic washout machine or device further comprises a heater or heating unit to heat the liquid or formulation in the master container or containers to about body temperature, or to about 37° C.,
- and optionally the master container or containers or the third tube comprise a filter or filters capable of separating or straining particulate matter from a liquid or formulation before it is infused into the colon;
- (c) a pump operably connected to the rectal speculum or catheter, the master container or containers, the third tube, the auxiliary container or containers and/or the second tube, where the pump when operational (turned on) moves or facilitates the flow of liquid or formulation contents of the rectal speculum or catheter, the master container or containers, the third tube, the auxiliary container or containers and/or the second tube, to the colon,
- and optionally the pump is a low pressure pump and/or a pressure adjustable pump, and optionally the pump further comprises a pressure gauge and pressure readings from the pump pressure gauge are transmitted to or are displayed to a reading device or screen on the colonic washout machine or device or remotely to a computer or a portable device, and optionally the portable device is a hand-held device or a smart phone, and optionally the pump is controlled remotely by use of a computer or a portable device or a foot pedal,
- and optionally the pump is capable of providing a pulsating movement of liquid or formulation through the rectal speculum or catheter into the colon, and optionally the pulsating movement of the pump is controlled remotely by use of a computer or a portable device or a foot pedal,
- (d) a first set of motor or motors operably connected to rollers or equivalent for massaging, shaking or vibrating an individual lying on or sitting in the colonic washout machine or device,
- and optionally the first set of motor or motors are controlled remotely by use of a computer or a portable device or a foot pedal,
- (f) a second set of motor or motors operably connected to the colonic washout machine or device and capable of moving the colonic washout machine or device in a tipping or side to side movement,
- and optionally the second set of motor or motors are controlled remotely by use of a computer or a portable device or a foot pedal;
- or
- (g) any combination of (a) to (f).
A rectal infusion or rectal aspiration tube or speculum comprising a first or distal end for inserting into the colon of an individual and a second proximal end comprising a fitting for connection to a container or source of liquid or formulation for infusion into the colon, wherein the first end of the rectal infusion or rectal aspiration tube comprises a plurality of exit holes, orifices or openings to allow passages of fluids,
- wherein the plurality of exit holes, orifices or openings are between about, or average from between about, 2 mm to 20 cm, and optionally the plurality of exit holes, orifices or openings are milled or made by a 3D printer,
- and optionally the plurality of openings are positioned at about 1, 2, and 3 cm from the distal tip, or a plurality of openings are positioned between about 0.5 to 20, or 1 to 10 cm from the distal tip of the rectal infusion or rectal aspiration tube, or speculum.
Dependencies are inferred from the claim text.